Detail akcie Novabridge Biosciences online

Business Summary: Novabridge Biosciences is a global biotechnology platform company. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. Its differentiated pipeline includes givastomig, a bispecific antibody (Claudin 18.2 x 4-1BB), and VIS-101, a bifunctional biologic, targeting VEGF-A and ANG2. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). VIS-101 is completing a large, randomized, dose-ranging Phase 2 study for wet AMD.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, NovaBridge Biosciences revenues was not reported. Net loss before extraordinary items decreased 60% to $15.5M. Lower net loss reflects Research and development expenses decrease of 53% to $7M (expense), Equity in loss of affiliates decrease from $1M (expense) to $0K, Stock-based Compensation in R&D decrease of 73% to $240K (expense).